Search clinical trials for: AFQ056
Total 25 results
-
Novartis PharmaceuticalsTerminatedFragile X SyndromeGermany, United States, Switzerland, Australia, Canada, Denmark, France, Italy, United Kingdom, Spain
-
Novartis PharmaceuticalsCompletedFragile X SyndromeUnited States, Switzerland, Germany, Australia, Canada, Denmark, France, Italy, Spain, United Kingdom
-
Novartis PharmaceuticalsCompletedFragile X SyndromeUnited States, Spain
-
Novartis PharmaceuticalsCompletedMild Moderate | or Severe Renal ImpairmentGermany
-
Novartis PharmaceuticalsCompletedHepatic ImpairmentGermany, United States, Hungary
-
Novartis PharmaceuticalsTerminatedFragile X SyndromeUnited States, Belgium, Australia, Israel, Switzerland, Germany, Denmark, Italy, Netherlands, Spain, Sweden, United Kingdom, France
-
Novartis PharmaceuticalsTerminatedEfficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing ChoreaChorea | Huntington's DiseaseGermany, United Kingdom
-
Novartis PharmaceuticalsCompletedFragile X SyndromeUnited States, Belgium, Australia, Israel, Switzerland, Germany, France, Canada, Denmark, Indonesia, Italy, Netherlands, Spain, Sweden, Turkey, United Kingdom
-
Elizabeth Berry-KravisNational Institute of Neurological Disorders and Stroke (NINDS); Novartis PharmaceuticalsCompleted
-
Yale UniversityCompletedFamilial Alcoholism VulnerabilityUnited States
-
Novartis PharmaceuticalsTerminatedPatient Diagnosed With OCD and Resistant to SSRI Treatment | Failed SSRI Over 12 Weeks at Appropriate DosesGermany, Switzerland, Bulgaria, United States, Czech Republic
-
Novartis PharmaceuticalsCompletedParkinson Disease | Dyskinesia, Drug-Induced | LevodopaItaly, United States, Australia, France, Germany, Canada
-
Novartis PharmaceuticalsCompletedParkinson Disease | Parkinsonian Disorders | Movement Disorders | Dyskinesias | Anti-Dyskinesia AgentsSpain, United States, Austria, Switzerland, France, Germany, Italy, Canada, Hungary, Slovakia
-
NovartisCompletedGastroesophageal Reflux DiseaseFrance, Germany, Belgium, Switzerland
-
NovartisCompletedEfficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease PatientsParkinson's Disease | L-dopa Induced DyskinesiaGermany
-
NovartisCompleted
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingFamilial Alcoholism VulnerabilityUnited States
-
Novartis PharmaceuticalsCompletedParkinson Disease | Parkinsonian Disorders | Movement Disorders | DyskinesiasSpain, France, Germany, Hungary, Italy, Canada, United States
-
NovartisCompletedParkinson Disease | DyskinesiasItaly, Spain, France, Germany, Finland, Japan, Australia, Canada
-
NovartisCompletedFragile X SyndromeFrance, Italy, Switzerland
-
Novartis PharmaceuticalsNational Institute on Drug Abuse (NIDA)WithdrawnCocaine Use Disorder
-
NovartisCompleted
-
Novartis PharmaceuticalsCompletedCocaine-related DisorderSpain, Argentina, Switzerland
-
Novartis PharmaceuticalsCompletedParkinson Disease | Parkinsonian Disorders | Movement Disorders | Dyskinesias | Anti-Dyskinesia AgentsSpain, United States, Austria, Switzerland, France, Germany, Italy, Hungary, Canada, Slovakia
-
NovartisCompleted